Krystal Novak Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3620 N 6th St, Beatrice, NE 68310 Phone: 402-228-4594 |
Dr. Nathan Clabaugh, RP Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 501 Court St, Beatrice, NE 68310 Phone: 402-223-3591 |
Jarred Vogel, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3620 N 6th St, Beatrice, NE 68310 Phone: 402-228-4594 |
Dr. Michael Richard Schmidt, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3620 N 6th St, Beatrice, NE 68310 Phone: 402-228-4594 |
Dr. Kent Allen Herzog, RP Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3620 N 6th St, Beatrice, NE 68310 Phone: 402-228-4594 |
Amber Lynn Fox, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3620 N 6th St, Beatrice, NE 68310 Phone: 402-228-4594 |
Dr. Mitchell E. Deines, RP Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 910 Court St, Beatrice, NE 68310 Phone: 402-223-4779 Fax: 402-223-5610 |
Suzanne Kay Byler, PHARMD RP Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2121 Jefferson St, Beatrice, NE 68310 Phone: 402-239-2241 |
Tyler Lee Lawson, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 910 Court St, Beatrice, NE 68310 Phone: 402-223-4779 Fax: 402-223-0156 |
Michael John Witulski Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3620 N 6th St, Beatrice, NE 68310 Phone: 402-228-4742 Fax: 402-228-4742 |
Kenneth Sapp, BS/RPH Pharmacist - Pharmacist Clinician (PhC)/ Clinical Pharmacy Specialist Medicare: Not Enrolled in Medicare Practice Location: 3620 N 6th St, Beatrice, NE 68310 Phone: 402-228-4594 |
News Archive
Diagnostic HYBRIDS announces the FDA clearance, for marketing under the 510(k) pre-notification process, of the Thyretain TSI Reporter BioAssay. Thyretain is an in vitro diagnostic use test that specifically detects auto-antibodies called thyroid stimulating immunoglobulins (TSI) in patient serum.
Dyax Corp. today announced the pricing of an underwritten public offering of 17,000,000 shares of its common stock at a price to the public of $3.25 per share. The gross proceeds from the sale of shares, after underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $51.8 million. The offering is expected to close on or about March 30, 2010, subject to customary closing conditions.
Movie villains from Norman Bates to Hannibal Lecter have popularized the notion of the psychopath as cold, cruel, lacking in empathy and beyond the reach of treatment.
The results of VOYAGER PAD found that people with peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing lower extremity revascularization-a procedure to treat blocked arteries in the leg-had a significant reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone.
Mad cow disease is caused by the accumulation of an abnormal protein, the prion, in the brain of an affected patient. Outside of the brain, very little is known about prions.
› Verified 4 days ago